Soligenix, Inc.
(NASDAQ : SNGX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
-0.53%292.591.4%$884.41m
AMGNAmgen, Inc.
1.86%224.801.3%$497.99m
CELGCelgene Corp.
0.79%110.431.3%$450.20m
GILDGilead Sciences, Inc.
-0.08%64.591.0%$391.68m
ILMNIllumina, Inc.
1.16%298.433.5%$314.25m
VRTXVertex Pharmaceuticals, Inc.
1.00%203.921.9%$295.00m
REGNRegeneron Pharmaceuticals, Inc.
1.14%348.202.6%$259.48m
EXASEXACT Sciences Corp.
0.35%80.8124.0%$201.57m
ALXNAlexion Pharmaceuticals, Inc.
0.67%109.742.0%$192.93m
SGENSeattle Genetics, Inc.
1.65%110.096.1%$126.08m
BMRNBioMarin Pharmaceutical, Inc.
1.77%76.664.3%$109.43m
AAgilent Technologies, Inc.
0.91%77.551.6%$101.80m
SRPTSarepta Therapeutics, Inc.
3.51%98.1114.6%$96.64m
MRTXMirati Therapeutics, Inc.
2.81%106.082.3%$93.53m
NBIXNeurocrine Biosciences, Inc.
1.47%112.485.0%$84.25m

Company Profile

Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.